PubMedopen access
Long-term benefits of upadacitinib for Atopic Dermatitis: deep responses in patient-reported outcomes over 140 weeks from the Measure Up 1 and Measure Up 2 clinical trials.
humans, patient reported outcome measures, heterocyclic compounds, 3-ring, dermatitis, atopic, quality of life, female
This document is indexed with metadata only — full text is not available in the archive for this record.
Open the official source ↗Related documents
Record · ID 174817
Retrieved via
Conceptio — every document is proof-bundled with source, license, and retrieval metadata.